References
- Cohen SA, Kellogg C, Equils O. Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development. Hum Vaccin Immunother. 2021;17(1):84–87. doi:10.1080/21645515.2020.1787074 .
- Yadav T, Srivastava N, Mishra G, Dhama K, Kumar S, Puri B, Saxena SK. Recombinant vaccines for COVID-19. Hum Vaccin Immunother. 2020;16(12):2905–12. doi:10.1080/21645515.2020.1820808 .
- Vashishtha VM, Kumar P. Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. Hum Vaccin Immunother. 2020;3:1–15. doi:10.1080/21645515.2020.1845524 .
- Coronavirus 2019‐nCoV, CSSE. Coronavirus 2019‐nCoV Global Cases by Johns Hopkins CSSE. [accessed 2021 Feb 16]. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 .
- Dipartimento della Protezione Civile. COVID-19 Situazione Italia [accessed 2021 Feb 16]. https://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1 .
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C; C4591001 Clinical Trial Group. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577 .
- Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50. doi:10.1056/NEJMoa2027906 .
- Carnovale C, Gringeri M, Battini V, Mosini G, Invernizzi E, Mazhar F, Bergamaschi F, Fumagalli M, Zuccotti G, Clementi E, et al. Beta-blocker associated hypoglycaemia: New insights from a real-world pharmacovigilance study. Brit Jnl Clinical Pharma. 2021;1–12... PMID: 33506522. doi:10.1111/bcp.14754 .